NICE guidance: Why not clozapine for treatment-refractory bipolar disorder? - Authors' reply

Richard Morriss; Evan Mayo-Wilson; Tim Kendall

doi:10.1016/S2215-0366(16)30098-0

NICE guidance: Why not clozapine for treatment-refractory bipolar disorder? - Authors' reply

Richard Morriss, Evan Mayo-Wilson, Tim Kendall

Bloomberg School of Public Health

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	503
Number of pages	1
Journal	The Lancet Psychiatry
Volume	3
Issue number	6
DOIs	https://doi.org/10.1016/S2215-0366(16)30098-0
State	Published - Jun 1 2016

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/S2215-0366(16)30098-0

Cite this

@article{565bdca992684be3b6ff88f67e47b888,

title = "NICE guidance: Why not clozapine for treatment-refractory bipolar disorder? - Authors' reply",

author = "Richard Morriss and Evan Mayo-Wilson and Tim Kendall",

note = "Funding Information: RM chaired the NICE Bipolar Disorder Guideline Development Group that was published in 2014 and reports personal fees from the UK National Collaborating Centre for Mental Health (NCCMH). EM-W received grants from the NCCMH during the period that this guideline was produced and from NICE. TK is Director of the NCCMH at present and during the production of the NICE guidelines on bipolar disorder and psychosis and schizophrenia. We declare no other competing interests.",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/S2215-0366(16)30098-0",

language = "English (US)",

volume = "3",

pages = "503",

journal = "The Lancet Psychiatry",

issn = "2215-0366",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - NICE guidance

T2 - Why not clozapine for treatment-refractory bipolar disorder? - Authors' reply

AU - Morriss, Richard

AU - Mayo-Wilson, Evan

AU - Kendall, Tim

N1 - Funding Information: RM chaired the NICE Bipolar Disorder Guideline Development Group that was published in 2014 and reports personal fees from the UK National Collaborating Centre for Mental Health (NCCMH). EM-W received grants from the NCCMH during the period that this guideline was produced and from NICE. TK is Director of the NCCMH at present and during the production of the NICE guidelines on bipolar disorder and psychosis and schizophrenia. We declare no other competing interests.

PY - 2016/6/1

Y1 - 2016/6/1

UR - http://www.scopus.com/inward/record.url?scp=84971383892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971383892&partnerID=8YFLogxK

U2 - 10.1016/S2215-0366(16)30098-0

DO - 10.1016/S2215-0366(16)30098-0

M3 - Letter

AN - SCOPUS:84971383892

SN - 2215-0366

VL - 3

SP - 503

JO - The Lancet Psychiatry

JF - The Lancet Psychiatry

IS - 6

ER -

NICE guidance: Why not clozapine for treatment-refractory bipolar disorder? - Authors' reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this